Diamyd Medical fully subscribes to its pro rata share in NextCell Pharma's rights issue
Diamyd Medical invests its pro rata share corresponding to approximately SEK 3.2 million in the associated company NextCell Pharma's ongoing rights issue, meaning that Diamyd Medical's book value of the holding in NextCell Pharma after the investment increases from approximately SEK 5.3 million to approximately SEK 8.5 million.Diamyd Medical is one of the main owners of NextCell Pharma with an ownership of 12.8%. NextCell Pharma is now carrying out a rights issue which, upon full subscription, will provide NextCell with approximately SEK 24.9 million before issue costs. “We